A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Authors
Corrie, PMatin, R
Gupta, Avinash
Qian, W
Wordsworth, S
Gibbons, E
Chhabra, A
Harman, C
Mather, C
Middleton, M
Affiliation
Oncology Centre, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, UKIssue Date
2018
Metadata
Show full item recordCitation
Corrie PG, Matin RN, Gupta A, Qian W, Wordsworth S, Gibbons E, et al. 1300TiP A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM). Ann Oncol. 2018;29(suppl_8):464.Journal
Annals of OncologyDOI
10.1093/annonc/mdy289.056Additional Links
https://dx.doi.org/10.1093/annonc/mdy289.056Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy289.056